Alixorexton is an oral selective orexin 2 receptor agonist expected to reduce excessive daytime sleepiness across hypersomnolence disorders such as narcolepsy.
Subcutaneous anifrolumab significantly reduces disease activity in patients with moderate to severe systemic lupus erythematosus.
ICE Announces Milestones Across its Data Business in 2025 Including Record Fixed Income Trading and Clearing VolumeThe Associated PressATLANTA & NEW YORK ATLANTA & NEW YORK–(BUSINESS WIRE)–Jan 6, 2026 ...
How can traders make better use of quote data across global credit markets? This analysis examines IBVAL, CBBT, and median ...
That's what makes walking into a well-stocked reloading room such a unique experience; one shelf is guaranteed to be buckling ...
Imperfect identity data can impair care quality and patient safety, hinder healthcare AI initiatives, and impact the bottom ...
First, institutions must ensure that synthetic datasets are continuously recalibrated against fresh, real-world evidence. The ...
We remain convinced that the use of this tool is worthwhile, even as critics warned that it’s flawed. Any verification system ...
Artivion stock is outperforming the med-tech sector. Here's what investors need to know about the company and its potential ...
The highest paid occupation is architectural & engineering management with a median income of $137,998. However, it’s ranked at No. 163 out of 231 in-demand jobs with 195 available openings. AL.com ...
The most-read ophthalmology biosimilar stories of 2025 included FDA approvals and real-world data. The continued expansion of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback